Carolin Fleischmann-Struzek1,2, Bianka Ditscheid3, Josephine Storch3, Norman Rose1,2, Melissa Spoden4, Christiane S Hartog5,6, Antje Freytag3. 1. Institute of Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany. 2. Center for Sepsis Control and Care, Jena University Hospital/Friedrich Schiller University Jena, Jena, Germany. 3. Institute of General Practice and Family Medicine, Jena University Hospital, Jena, Germany. 4. Research Institute of the Local Health Care Funds (AOK), Berlin, Germany. 5. Department of Anesthesiology and Operative Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany. 6. Klinik Bavaria, Kreischa, Germany.
New or recurrent infections and sepsis are leading causes of rehospitalization after sepsis.[1] Although persistent immunosuppression after sepsis is considered a causative factor, patient-inherent risk factors may also contribute to increased risk of recurrent severe infections.[2] The burden of infection in these patients presepsis is unknown. We analyzed the change in infection-related hospitalizations and outpatient drug prescriptions presepsis vs postsepsis.
Methods
This retrospective cohort study was based on health claims data of AOK, a statutory health insurance provider in Germany, for the years 2011 to 2015. The study was approved by the Jena University Hospital Institutional Review Board; informed consent was waived owing to deidentified patient data. This study followed followed the STROBE reporting guideline.Inpatient sepsis cases were identified by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, German Modification (ICD-10-GM) codes between January 1, 2013, and December 31, 2014, among AOK beneficiaries who were older than 15 years and had no sepsis in the 24 months before index hospitalization. We analyzed hospitalizations and drug prescriptions in the 12 months presepsis and postsepsis among sepsis survivors. Hospitalizations were classified as infection- or sepsis-related according to requisite ICD-10-GM hospital discharge diagnoses.[3] Intensive care unit (ICU) treatment was identified by Operation and Procedure Classification System codes for intensive care complex treatment (8-980, 8-98f, 8-98d, 8-98c). We analyzed total drug prescriptions and prescriptions of anti-infectives according to Anatomic Therapeutical Chemical codes (J01, J02, J04A, J05, A07AA, P01AB). Presepsis and postsepsis outcomes were compared using a 2-sided McNemar χ2 test; statistical significance was set at α = .05. Statistical analyses were conducted using SAS Enterprise Guide, version 7.1 (SAS Institute Inc).
Results
Among 23 million AOK beneficiaries, we identified 159 684 sepsis patients, 116 507 of whom survived hospitalization. The mean (SD) age was 73.0 (13.3) years; 52.1% were men and 47.9% were women. Among the survivors, 32.5% had severe sepsis, 27.7% were treated in an ICU, and 7.4% had no preexisting impairments. In the 12 months postsepsis, 66.8% of survivors were rehospitalized and 45.0% were rehospitalized with infection (67.4% of all rehospitalizations). Among all survivors, 11.9% were rehospitalized for recurrent sepsis, 25.9% of whom were admitted to an ICU; 56.6% of sepsis survivors received anti-infective treatment in an outpatient setting.Although hospitalization rates increased by 3.4% from 63.4% in the 12 months presepsis to 66.8% in the 12 months postsepsis (P < .001), the proportion of patients with infection-related hospitalizations increased by 9.6% (presepsis, 35.4% vs postsepsis, 45.0%; P < .001). The proportion of patients with device-related infections nearly doubled from presepsis to postsepsis (Figure). Total outpatient drug prescriptions decreased (97.5% vs 94.1%; P < .001), but the proportion of patients with at least 1 anti-infective prescription increased by 4.0% (52.6% vs 56.6%; P < .001). The increase in hospitalization and infection-related hospitalization rates was highest in patients without preexisting medical, cognitive, or psychological impairments (hospitalization rate, from 22.5% to 54.6% [a 32.1% increase]; infection-related hospitalization rate, from 6.4% to 31.4% [a 25.0% increase]) (Table). Prescriptions of anti-infectives increased consistently across subgroups and were most prominent in the subgroup of survivors without preexisting impairments (16.7%).
Figure.
Comparison of Presepsis and Postsepsis Source of Infection Among Patients With Infection-Related Hospitalization
Table.
Comparison of Hospitalizations, Infection-Related Hospitalizations, and Drug Prescriptions Among Patients Before and After Sepsis Hospitalization
Variablea
Patient group
Total
Patients with ≥1 hospitalizations
Patients with infection-related hospitalizations
Patients with ≥1 drug prescriptions
Patients with anti-infective prescriptions
No.
No. (%)
P value
No. (%)
P value
No. (%)
P value
No. (%)
P value
Sepsis
Severe
Presepsis
37 840
23 800 (62.9)
<.001
13 474 (35.6)
<.001
36 747 (97.1)
<.001
19 104 (50.5)
<.001
Postsepsis
37 840
25 409 (67.1)
17 757 (46.9)
34 472 (91.1)
20 074 (53.1)
Nonsevere
Presepsis
78 667
50 082 (63.7)
<.001
27 785 (35.3)
<.001
76 805 (97.6)
<.001
42 121 (53.5)
<.001
Postsepsis
78 667
52 433 (66.6)
34 688 (44.1)
75 196 (95.6)
45 908 (58.4)
ICU admission
Yes
Presepsis
32 238
20 305 (63.0)
<.001
10 970 (34.0)
<.001
30 980 (96.1)
<.001
15 354 (47.6)
<.001
Postsepsis
32 238
22 407 (69.5)
15 426 (47.8)
29 371 (91.1)
16 440 (51.0)
No
Presepsis
84 269
53 577 (63.6)
<.001
30 289 (35.9)
<.001
82 572 (98.0)
<.001
45 871 (54.4)
<.001
Postsepsis
84 269
55 435 (65.8)
37 019 (43.9)
80 297 (95.3)
49 542 (58.8)
Prior impairment
Yes
Presepsis
107 885
71 943 (66.7)
<.001
40 710 (37.7)
<.001
106 943 (99.1)
<.001
58 247 (54.0)
<.001
Postsepsis
107 885
73 137 (67.8)
49 735 (46.1)
101 708 (94.3)
61 566 (57.1)
No
Presepsis
8622
1939 (22.5)
<.001
549 (6.4)
<.001
6609 (76.6)
<.001
2978 (34.5)
<.001
Postsepsis
8622
4705 (54.6)
2710 (31.4)
7960 (92.3)
4416 (51.2)
Age, y
<40
Presepsis
2649
1392 (52.5)
<.001
703 (26.5)
<.001
2381 (89.9)
<.001
1610 (60.8)
<.001
Postsepsis
2649
1560 (58.9)
903 (34.1)
2461 (92.9)
1734 (65.4)
40-65
Presepsis
25 860
15 928 (61.6)
<.001
8406 (32.5)
<.001
24 472 (94.6)
.58
14 214 (55.0)
<.001
Postsepsis
25 860
17 703 (68.4)
11 272 (43.6)
24 445 (94.5)
15 133 (58.5)
66-80
Presepsis
51 787
33 889 (65.4)
<.001
19 076 (36.8)
<.001
50 831 (98.2)
<.001
27 158 (52.4)
<.001
Postsepsis
51 787
35 774 (69.1)
24 382 (47.1)
48 726 (94.1)
29 540 (57.0)
>80
Presepsis
36 211
22 673 (62.6)
.29
13 074 (36.1)
<.001
35 868 (99.0)
<.001
18 243 (50.4)
<.001
Postsepsis
36 211
22 805 (63.0)
15 888 (43.9)
34 036 (94.0)
19 575 (54.0)
All presepsis and postsepsis periods are 12 months.
All presepsis and postsepsis periods are 12 months.
Discussion
This study found that infection-related hospitalizations affected 2 of every 3 sepsis survivors in Germany. Although hospitalizations among our study cohort increased by 9.6% postsepsis, more than half of these patients had already contracted infectious diseases requiring hospitalization prior to sepsis. This finding suggests that many sepsis patients are at risk for severe infections presepsis—presumably owing to preexisting immune dysfunction—and that septic insults may exacerbate their risk of developing severe infections and recurrent sepsis.[4] Furthermore, patients without prior impairments and low rates of presepsis infection–related hospitalizations and drug prescriptions had these rates increase substantially postsepsis.This study has some limitations. First, the validity of health claims diagnoses relies on coding quality. Second, subgroup comparisons should be interpreted within the context of differential mortality rates among survivors. Regardless, our findings highlight the need for preventive measures—particularly vaccinations and programs to prevent device-related infections—as well as early recognition and education regarding symptoms among all sepsis survivors and at-risk patients in the general population.
Authors: Tisha Wang; Ariss Derhovanessian; Sharon De Cruz; John A Belperio; Jane C Deng; Guy Soo Hoo Journal: J Intensive Care Med Date: 2012-12-26 Impact factor: 3.510
Authors: Carolin Fleischmann-Struzek; Norman Rose; Antje Freytag; Melissa Spoden; Hallie C Prescott; Anna Schettler; Lisa Wedekind; Bianka Ditscheid; Josephine Storch; Sebastian Born; Peter Schlattmann; Christian Günster; Konrad Reinhart; Christiane S Hartog Journal: JAMA Netw Open Date: 2021-11-01